Evidence map›Paper›PMID 34677336›Full record

ArticleBiosensors2021

Mesoporous One-Component Gold Microshells as 3D SERS Substrates.

Anna S Vikulina, Inna Y Stetsyura, M Serdar Onses, Erkan Yilmaz, Andre G Skirtach, Dmitry Volodkin

Abstract read
In one paragraph

Article in Biosensors, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. SERS-Based Nano- and Microsystems Toward Biomedical Applications.Small (Weinheim an der Bergstrasse, Germany) · 2026
    Review
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Anna S VikulinaDepartment of Theory and Bio-Systems, Max Planck Institute of Colloids and Interfaces, Am Mühlenberg 1, 14476 Potsdam, Germany.
Inna Y StetsyuraFraunhofer Institute for Cell Therapy and Immunology, Branch Bioanalytics and Bioprocesses, Am Mühlen-berg 13, 14476 Potsdam, Germany.
M Serdar OnsesERNAM-Erciyes University Nanotechnology Application and Research Center, Kayseri 38039, Turkey.
Erkan YilmazERNAM-Erciyes University Nanotechnology Application and Research Center, Kayseri 38039, Turkey.
Andre G SkirtachDepartment of Biotechnology, Ghent University, Coupure Links 653, 9000 Ghent, Belgium.ORCID 0000-0002-4468-7620
Dmitry VolodkinSchool of Science and Technology, Nottingham Trent University, Clifton Lane, Nottingham NG11 8NS, UK.ORCID 0000-0001-7474-5329

Funding

Alexander von Humboldt-Stiftung Humboldt Postdoctoral FellowshipAlexander von Humboldt-Stiftung Sofja Kovalevskaja programFonds Wetenschappelijk Onderzoek FWO-Vlaanderen G043219Nottingham Trent University SPF programme 2019-2020Staedtler Stiftung Support to FAUUniversiteit Gent BAS094-18, BOF14/IOP/003
6 · The paper itself

Abstract

Surface-enhanced Raman scattering (SERS) is a powerful analytical tool for label-free analysis that has found a broad spectrum of applications in material, chemical, and biomedical sciences. In recent years, a great interest has been witnessed in the rational design of SERS substrates to amplify Raman signals and optionally allow for the selective detection of analytes, which is especially essential and challenging for biomedical applications. In this study, hard templating of noble metals is proposed as a novel approach for the design of one-component tailor-made SERS platforms. Porous Au microparticles were fabricated via dual ex situ adsorption of Au nanoparticles and in situ reduction of HAuCl

Indexed as

GoldMetal NanoparticlesSerum Albumin, BovineSpectrum Analysis, RamanGoldSerum Albumin, Bovinecalcium carbonatehard templatingmicroparticlesRaman spectroscopyvaterite

Identifiers

PMID34677336
PMCPMC8533941

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.